Status:
COMPLETED
Study Evaluating the Gastrointestinal Safety of PLA-695 Compared to Placebo and Naproxen
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to provide an initial assessment of the gastrointestinal safety of a 7-day regimen of PLA-695 compared to placebo or naproxen.
Eligibility Criteria
Inclusion
- Healthy men or women of nonchildbearing potential, aged 18 to 60 years.
Exclusion
- Abnormal baseline endoscopy.
- Positive Helicobacter pylori serology.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00366262
Start Date
June 1 2006
End Date
March 1 2007
Last Update
August 5 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Houston, Texas, United States, 77074